Morgan Stanley Pds Biotechnology Corp Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Morgan Stanley holds 27,432 shares of PDSB stock, worth $57,332. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,432
Previous 73,988
62.92%
Holding current value
$57,332
Previous $216,000
51.85%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PDSB
# of Institutions
64Shares Held
4.32MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$3.18 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$1.02 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$867,5860.0% of portfolio
-
Inspirion Wealth Advisors, LLC344KShares$719,7830.18% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$489,4960.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $59.5M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...